prulifloxacin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Bacterial Gastroenteritis
Conditions
Acute Bacterial Gastroenteritis
Trial Timeline
Dec 1, 2006 → Aug 1, 2008
NCT ID
NCT00448422About prulifloxacin
prulifloxacin is a phase 3 stage product being developed by Merck for Acute Bacterial Gastroenteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00448422. Target conditions include Acute Bacterial Gastroenteritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00448422 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Bacterial Gastroenteritis